{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:51:07Z","timestamp":1793393467974,"version":"4.5.0"},"reference-count":202,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Dihydroartemisinin (or artenimol)\u2013piperaquine is one of the six artemisinin-based combination therapies recommended in uncomplicated malaria treatment. However, artemisinin partial resistance has been reported in Cambodia, Laos, Vietnam, India, and, recently, in Africa. Polymorphisms in the Pfk13 gene have been described as molecular markers of artemisinin resistance and the amplification of the plasmepsine II\/III (Pfpmp2\/Pfpmp3) gene has been associated with piperaquine resistance. However, some therapeutic failures with this combination remain unexplained by strains\u2019 characterization. We provide an overview on the use of dihydroartemisinin\u2013piperaquine in malaria treatment and discuss tools available to monitor its efficacy.<\/jats:p>","DOI":"10.3390\/jcm13226828","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T08:09:28Z","timestamp":1731485368000},"page":"6828","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dihydroartemisinin\u2013Piperaquine Combination in the Treatment of Uncomplicated Plasmodium falciparum Malaria: Update on Clinical Failures in Africa and Tools for Surveillance"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-8923","authenticated-orcid":false,"given":"Oc\u00e9ane","family":"Delandre","sequence":"first","affiliation":[{"name":"Unit\u00e9 Parasitologie et Entomologie, D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 13005 Marseille, France"},{"name":"Aix Marseille Univ, SSA, AP-HM, RITMES, 13005 Marseille, France"},{"name":"IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-3803","authenticated-orcid":false,"given":"Bruno","family":"Pradines","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Parasitologie et Entomologie, D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 13005 Marseille, France"},{"name":"Aix Marseille Univ, SSA, AP-HM, RITMES, 13005 Marseille, France"},{"name":"IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Centre National de R\u00e9f\u00e9rence du Paludisme, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Javelle","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Parasitologie et Entomologie, D\u00e9partement Microbiologie et Maladies Infectieuses, Institut de Recherche Biom\u00e9dicale des Arm\u00e9es, 13005 Marseille, France"},{"name":"Aix Marseille Univ, SSA, AP-HM, RITMES, 13005 Marseille, France"},{"name":"IHU M\u00e9diterran\u00e9e Infection, 13005 Marseille, France"},{"name":"Centre National de R\u00e9f\u00e9rence du Paludisme, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, November 09). World Malaria Report. Available online: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"ref_2","unstructured":"European Centre for Disease Prevention and Control (2024, August 21). Malaria\u2014Annual Epidemiological Report for 2021. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/malaria-annual-epidemiological-report-2021."},{"key":"ref_3","first-page":"21","article-title":"Le paludisme, une symptomatologie asp\u00e9cifique","volume":"57","author":"Danthu","year":"2018","journal-title":"Actual. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1086\/338235","article-title":"Imported Falciparum malaria in Europe: Sentinel surveillance data from the European Network on surveillance of imported infectious diseases","volume":"34","author":"Jelinek","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1098\/rstb.2009.0273","article-title":"The evolution, metabolism and functions of the apicoplast","volume":"365","author":"Lim","year":"2010","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.pt.2022.02.010","article-title":"Plasmodium\u2019s bottomless pit: Properties and functions of the malaria parasite\u2019s digestive vacuole","volume":"38","author":"Matz","year":"2022","journal-title":"Trends Parasitol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0163-7258(91)90074-V","article-title":"The dynamics of drug resistance in Plasmodium falciparum","volume":"50","author":"Wernsdorfer","year":"1991","journal-title":"Pharmacol. Ther."},{"key":"ref_8","first-page":"647","article-title":"Plasmodium falciparum susceptibility to antimalarial drugs: Global data issued from the Pasteur Institutes international network","volume":"29","author":"Ariey","year":"2013","journal-title":"Med. Sci."},{"key":"ref_9","first-page":"51","article-title":"La r\u00e9sistance aux antipaludiques","volume":"2010","author":"Pradines","year":"2010","journal-title":"Rev. Francoph. Des Lab."},{"key":"ref_10","unstructured":"WHO Drug Resistance in Malaria (2024, November 09). 2001, Volume 32. Available online: https:\/\/iris.who.int\/handle\/10665\/66847."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa2211803","article-title":"Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda","volume":"389","author":"Conrad","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12936-023-04812-y","article-title":"Molecular surveillance of Kelch 13 polymorphisms in Plasmodium falciparum isolates from Kenya and Ethiopia","volume":"23","author":"Jeang","year":"2024","journal-title":"Malar. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pt.2023.11.007","article-title":"Plasmodium falciparum ring-stage plasticity and drug resistance","volume":"40","author":"Platon","year":"2024","journal-title":"Trends Parasitol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chom.2019.06.001","article-title":"Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum","volume":"26","author":"Ross","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/jm00035a003","article-title":"Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: The importance of a carbon-centered radical for antimalarial activity","volume":"37","author":"Posner","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpddr.2021.05.007","article-title":"Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook","volume":"16","author":"Siddiqui","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, L., Zheng, Z., Liu, H., Wang, X., Qu, S., Yang, Y., Deng, S., Zhang, Y., Tuo, L., and Zhao, Y. (2021). Combined Transcriptome and Proteome Profiling for Role of pfEMP1 in Antimalarial Mechanism of Action of Dihydroartemisinin. Microbiol. Spectr., 9.","DOI":"10.1128\/Spectrum.01278-21"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200565010-00004","article-title":"Piperaquine: A resurgent antimalarial drug","volume":"65","author":"Davis","year":"2005","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/11203910-000000000-00000","article-title":"Dihydroartemisinin\/Piperaquine: A review of its use in the treatment of uncomplicated Plasmodium falciparum malaria","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of Artemisinin-Resistant Malaria in Western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"World Health Organization (2024, November 09). Status Report on Artemisinin and ACT Resistance. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/274362\/WHO-CDS-GMP-2018.18-eng.pdf."},{"key":"ref_24","first-page":"45","article-title":"In vitro antimalarial activity of methylene blue against field isolates of Plasmodium falciparum from children in Southwest Nigeria","volume":"126","author":"Ademowo","year":"2007","journal-title":"Indian J. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1056\/NEJMc1713777","article-title":"Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India","volume":"379","author":"Das","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1473-3099(12)70181-0","article-title":"Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: A parasite clearance rate study","volume":"12","author":"Amaratunga","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"ref_29","unstructured":"(2024, November 09). WHO Malaria: Artemisinin Partial Resistance. Available online: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/artemisinin-resistance."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","article-title":"Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: An observational cohort study","volume":"15","author":"Spring","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: In-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(14)70777-7","article-title":"Artemisinin resistance in Plasmodium falciparum","volume":"14","author":"Amaratunga","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12799","DOI":"10.1073\/pnas.1812317115","article-title":"Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility","volume":"115","author":"Demas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Delandre, O., Gendrot, M., Fonta, I., Mosnier, J., Benoit, N., Amalvict, R., Gomez, N., Madamet, M., and Pradines, B. (2021). Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081273"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1907142116","article-title":"An alternative dogma on reduced artemisinin susceptibility: A new shadow from east to west","volume":"116","author":"Velavan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: A phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(23)00502-9","article-title":"Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in French Guiana: A descriptive epidemiological study","volume":"24","author":"Florimond","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1073\/pnas.1507142112","article-title":"Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt","volume":"112","author":"Pelleau","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","article-title":"A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms","volume":"374","author":"Khim","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12936-016-1095-y","article-title":"Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children","volume":"15","author":"Muwanguzi","year":"2016","journal-title":"Malar. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ijantimicag.2017.01.032","article-title":"Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal","volume":"49","author":"Madamet","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yobi, D.M., Kayiba, N.K., Mvumbi, D.M., Boreux, R., Bontems, S., Kabututu, P.Z., De Mol, P., Speybroeck, N., Mvumbi, G.L., and Hayette, M.-P. (2020). The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237791"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Aninagyei, E., Duedu, K.O., Rufai, T., Tetteh, C.D., Chandi, M.G., Ampomah, P., and Acheampong, D.O. (2020). Characterization of putative drug resistant biomarkers in Plasmodium falciparum isolated from Ghanaian blood donors. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05266-2"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: An open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"Uwimana","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4269\/ajtmh.16-0483","article-title":"Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010\u20132015","volume":"95","author":"Tacoli","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3201\/eid2701.203527","article-title":"Increase in kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda","volume":"27","author":"Bergmann","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3201\/eid2804.212269","article-title":"In Vitro confirmation of artemisinin resistance in Plasmodium falciparum from patient isolates, Southern Rwanda, 2019","volume":"28","author":"Oliveira","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0129923","DOI":"10.1128\/aac.01299-23","article-title":"Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda","volume":"68","author":"Schallenberg","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","article-title":"High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine","volume":"225","author":"Straimer","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"ofad149","DOI":"10.1093\/ofid\/ofad149","article-title":"Examining the Early Distribution of the Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda","volume":"10","author":"Kirby","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Schreidah, C., Giesbrecht, D., Gashema, P., Young, N., Munyaneza, T., Muvunyi, C.M., Thwai, K., Mazarati, J.-B., Bailey, J., and Juliano, J.J. (2023). Expansion of Artemisinin Partial Resistance Mutations and Lack of Histidine Rich Protein-2 and -3 Deletions in Plasmodium falciparum infections from Rukara, Rwanda. medRxiv.","DOI":"10.1101\/2023.12.17.23300081"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01234-19","DOI":"10.1128\/AAC.01234-19","article-title":"The Diversity of the Plasmodium falciparum K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda","volume":"63","author":"Conrad","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e01818-18","DOI":"10.1128\/AAC.01818-18","article-title":"Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda","volume":"63","author":"Asua","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda","volume":"223","author":"Asua","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1038\/s41467-022-33873-x","article-title":"Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda","volume":"13","author":"Tumwebaze","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Angwe, M.K., Mwebaza, N., Nsobya, S.L., Vudriko, P., Dralabu, S., Omali, D., Tumwebaze, M.A., and Ocan, M. (2024). Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda. PLoS ONE, 19.","DOI":"10.1101\/2024.04.26.24306433"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0165923","DOI":"10.1128\/aac.01659-23","article-title":"Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant Plasmodium falciparum in Uganda","volume":"68","author":"Awor","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bwire, G.M., Ngasala, B., Mikomangwa, W.P., Kilonzi, M., and Kamuhabwa, A.A.R. (2020). Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-60549-7"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Juliano, J.J., Giesbrecht, D.J., Simkin, A., Fola, A.A., Lyimo, B.M., Pereus, D., Bakari, C., Madebe, R.A., Seth, M.D., and Mandara, C.I. (2023). Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv.","DOI":"10.1101\/2023.11.07.23298207"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Young, N.W., Gashema, P., Giesbrecht, D., Munyaneza, T., Maisha, F., Mwebembezi, F., Budodo, R., Leonetti, A., Crudale, R., and Iradukunda, V. (2024). High frequency of artemisinin partial resistance mutations in the great lake region revealed through rapid pooled deep sequencing. medRxiv.","DOI":"10.1101\/2024.04.29.24306442"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ishengoma, D.S., Mandara, C.I., Bakari, C., Fola, A.A., Madebe, R.A., Seth, M.D., Francis, F., Buguzi, C., Moshi, R., and Garimo, I. (2024). Evidence of artemisinin partial resistance in North-western Tanzania: Clinical and drug resistance markers study. medRxiv.","DOI":"10.2139\/ssrn.4726181"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12936-023-04517-2","article-title":"Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment","volume":"22","author":"Maniga","year":"2023","journal-title":"Malar. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.15-0477","article-title":"A Unique Plasmodium falciparum K13 Gene Mutation in Northwest Ethiopia","volume":"94","author":"Bayih","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","article-title":"Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia","volume":"8","author":"Fola","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","article-title":"Increasing prevalence of artemisinin-resistant hrp2-negative malaria in eritrea","volume":"389","author":"Mihreteab","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/cid\/ciac162","article-title":"Circulation of an artemisinin-resistant malaria lineage in a traveler returning from east Africa to France","volume":"75","author":"Bailly","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00802-19","DOI":"10.1128\/AAC.00802-19","article-title":"Plasmodium falciparum Kelch propeller polymorphisms in Clinical Isolates from Ghana from 2007 to 2016","volume":"63","author":"Matrevi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Matrevi, S.A., Tandoh, K.Z., Bruku, S., Opoku-Agyeman, P., Adams, T., Ennuson, N.A., Asare, B., Hagan, O.C.K., Abuaku, B., and Koram, K.A. (2022). Novel pfk13 polymorphisms in Plasmodium falciparum population in Ghana. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-11790-9"},{"key":"ref_70","first-page":"41","article-title":"Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo","volume":"139","author":"Baraka","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-5793(98)01557-9","article-title":"A Plasmodium falciparum novel gene encoding a coronin-like protein which associates with actin filaments","volume":"441","author":"Tardieux","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12936-015-0801-5","article-title":"Plasmodium falciparum coronin organizes arrays of parallel actin filaments potentially guiding directional motility in invasive malaria parasites","volume":"14","author":"Olshina","year":"2015","journal-title":"Malar. J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bane, K.S., Lepper, S., Kehrer, J., Sattler, J.M., Singer, M., Reinig, M., Klug, D., Heiss, K., Baum, J., and Mueller, A.-K. (2016). The Actin filament-binding protein coronin regulates motility in Plasmodium sporozoites. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005710"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ullah, I., Farringer, M.A., Burkhard, A.Y., Hathaway, E., Khushu, M., Willett, B.C., Shin, S.H., Sharma, A.I., Martin, M.C., and Shao, K.L. (2024). Artemisinin resistance mutations in Pfcoronin impede hemoglobin uptake. bioRxiv.","DOI":"10.1101\/2023.12.22.572193"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12936-021-03987-6","article-title":"Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum","volume":"20","author":"Owoloye","year":"2021","journal-title":"Malar. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"106190","DOI":"10.1016\/j.ijantimicag.2020.106190","article-title":"Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal","volume":"56","author":"Delandre","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Matrevi, S.A., Adams, T., Tandoh, K.Z., Opoku-Agyeman, P., Bruku, S., Ennuson, N.A., Apau-Danso, P.K., Fiagbedzi, E., Avornyo, M., and Myers, C.J. (2024). Putative molecular markers of Plasmodium falciparum resistance to antimalarial drugs in malaria parasites from Ghana. Front. Epidemiol., 4.","DOI":"10.3389\/fepid.2024.1279835"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ajibaye, O., Olukosi, Y.A., Oriero, E.C., Oboh, M.A., Iwalokun, B., Nwankwo, I.C., Nnam, C.F., Adaramoye, O.V., Chukwemeka, S., and Okanazu, J. (2024). Detection of novel Plasmodium falciparum coronin gene mutations in a recrudescent ACT-treated patient in South-Western Nigeria. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1366563"},{"key":"ref_79","first-page":"445","article-title":"Treatment failure in a UK malaria patient harbouring genetically variant Plasmodium falciparum from Uganda with reduced in vitro susceptibility to artemisinin and lumefantrine","volume":"78","author":"Pratt","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"taad165","DOI":"10.1093\/jtm\/taad165","article-title":"Failure of artemether-lumefantrine therapy in travellers returning to Belgium with Plasmodium falciparum malaria: An observational case series with genomic analysis","volume":"31","author":"Pierreux","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"taad114","DOI":"10.1093\/jtm\/taad114","article-title":"Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria","volume":"30","author":"Grossman","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_82","first-page":"59","article-title":"Implications des pompes membranaires de Plasmodium falciparum dans le transport et la r\u00e9sistance aux antipaludiques","volume":"2020","author":"Pradines","year":"2020","journal-title":"Rev. Francoph. Des. Lab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","article-title":"Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance","volume":"6","author":"Fidock","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1126\/science.1074045","article-title":"Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcrt Mutations","volume":"298","author":"Sidhu","year":"2002","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e00303-17","DOI":"10.1128\/mBio.00303-17","article-title":"A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine","volume":"8","author":"Dhingra","year":"2017","journal-title":"mBio"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","article-title":"Plasmodium falciparum resistance to piperaquine driven by PfCRT","volume":"19","author":"Dhingra","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-019-1795-x","article-title":"Structure and drug resistance of the Plasmodium falciparum transporter PfCRT","volume":"576","author":"Kim","year":"2019","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/infdis\/jiac365","article-title":"Mutant PfCRT Can mediate piperaquine resistance in african plasmodium falciparum with reduced fitness and increased susceptibility to other antimalarials","volume":"226","author":"Wicht","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased pipera-quine Sensitivity","volume":"216","author":"Agrawal","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/infdis\/jiab055","article-title":"Distribution and temporal dynamics of Plasmodium falciparum chloroquine resistance transporter mutations associated with piperaquine resistance in Northern Cambodia","volume":"224","author":"Shrestha","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Boonyalai, N., Thamnurak, C., Sai-Ngam, P., Ta-Aksorn, W., Arsanok, M., Uthaimongkol, N., Sundrakes, S., Chattrakarn, S., Chaisatit, C., and Praditpol, C. (2021). Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-92735-6"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e0112121","DOI":"10.1128\/AAC.01121-21","article-title":"Evolution of multidrug resistance in Plasmodium falciparum: A longitudinal study of genetic resistance markers in the Greater Mekong Subregion","volume":"65","author":"Imwong","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1473-3099(23)00564-9","article-title":"Determinants of piperaquine-resistant malaria in South America","volume":"24","author":"Mok","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Vanhove, M., Schwabl, P., Clementson, C., Early, A.M., Laws, M., Anthony, F., Florimond, C., Mathieu, L., James, K., and Knox, C. (2024). Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana. bioRxiv.","DOI":"10.1101\/2024.01.31.578156"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-020-03281-x","article-title":"Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates","volume":"19","author":"Foguim","year":"2020","journal-title":"Malar. J."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Okombo, J., Mok, S., Qahash, T., Yeo, T., Bath, J., Orchard, L.M., Owens, E., Koo, I., Albert, I., and Llin\u00e1s, M. (2022). Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010926"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e02309-17","DOI":"10.1128\/AAC.02309-17","article-title":"Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine","volume":"62","author":"Mukherjee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","article-title":"Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: A genotype-phenotype association study","volume":"17","author":"Amato","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12936-016-1097-9","article-title":"Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites","volume":"15","author":"Ponsuwanna","year":"2016","journal-title":"Malar. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12936-020-03249-x","article-title":"Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2\/3 copy number variation in Plasmodium falciparum","volume":"19","author":"Ansbro","year":"2020","journal-title":"Malar. J."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Rovira-Vallbona, E., Kattenberg, J.H., Hong, N.V., Guetens, P., Imamura, H., Monsieurs, P., Chiheb, D., Erhart, A., Phuc, B.Q., and Xa, N.X. (2023). Molecular surveillance of Plasmodium falciparum drug-resistance markers in Vietnam using multiplex amplicon sequencing (2000\u20132016). Sci. Rep., 13.","DOI":"10.1038\/s41598-023-40935-7"},{"key":"ref_102","first-page":"2272","article-title":"Efficacy of dihydroartemisinin\/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam","volume":"75","author":"Kattenberg","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e0027621","DOI":"10.1128\/AAC.00276-21","article-title":"Pyronaridine-artesunate (pyramax) for treatment of artemisinin- and piperaquine-resistant Plasmodium falciparum in the central highlands of Vietnam","volume":"65","author":"Manh","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Duru, V., Khim, N., Leang, R., Kim, S., Domergue, A., Kloeung, N., Ke, S., Chy, S., Eam, R., and Khean, C. (2015). Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: Retrospective and prospective investigations. BMC Med., 13.","DOI":"10.1186\/s12916-015-0539-5"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","article-title":"Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: A prospective clinical, pharmacological, and genetic study","volume":"19","author":"Imwong","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e00374-18","DOI":"10.1128\/AAC.00374-18","article-title":"Absence of a high level of duplication of the Plasmepsin II gene in Africa","volume":"62","author":"Robert","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","article-title":"African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker","volume":"18","author":"Leroy","year":"2019","journal-title":"Malar. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"taaa231","DOI":"10.1093\/jtm\/taaa231","article-title":"Artemisinin resistance surveillance in African Plasmodium falciparum isolates from imported malaria cases to Italy","volume":"28","author":"Bartoli","year":"2021","journal-title":"J. Travel Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e02445-18","DOI":"10.1128\/AAC.02445-18","article-title":"Baseline ex vivo and molecular responses of Plasmodium falciparum isolates to piperaquine before implementation of dihydroartemisinin-piperaquine in Senegal","volume":"63","author":"Robert","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e01516-17","DOI":"10.1128\/AAC.01516-17","article-title":"Changing Antimalarial Drug Sensitivities in Uganda","volume":"61","author":"Rasmussen","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12936-021-04021-5","article-title":"Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda","volume":"20","author":"Ebong","year":"2021","journal-title":"Malar. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/tmi.13929","article-title":"Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM_net countries of the Eastern Mediterranean Region 2016-2020: Clinical and genetic studies","volume":"28","author":"Adam","year":"2023","journal-title":"Trop. Med. Int. Health"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3201\/eid2401.170864","article-title":"Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015","volume":"24","author":"Gupta","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e0034624","DOI":"10.1128\/aac.00346-24","article-title":"Antimalarial resistance risk in Mozambique detected by a novel quadruplex droplet digital PCR assay","volume":"68","author":"Brown","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Wakoli, D.M., Ondigo, B.N., Ochora, D.O., Amwoma, J.G., Okore, W., Mwakio, E.W., Chemwor, G., Juma, J., Okoth, R., and Okudo, C. (2022). Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs. BMC Med., 20.","DOI":"10.1186\/s12916-022-02652-2"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","article-title":"Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017","volume":"17","author":"Davlantes","year":"2018","journal-title":"Malar. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","article-title":"Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania","volume":"17","author":"Kakolwa","year":"2018","journal-title":"Malar. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.actatropica.2018.06.016","article-title":"Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone","volume":"185","author":"Smith","year":"2018","journal-title":"Acta Trop."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3201\/eid2408.180370","article-title":"Plasmodium falciparum plasmepsin 2 duplications, West Africa","volume":"24","author":"Inoue","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","article-title":"Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine","volume":"9","author":"Loesbanluechai","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"eadi2364","DOI":"10.1126\/sciadv.adi2364","article-title":"Mapping the genomic landscape of multidrug resistance in Plasmodium falciparum and its impact on parasite fitness","volume":"9","author":"Mok","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_122","first-page":"585","article-title":"Standardisation of the in vitro chemosensitivity test for Plasmodium falciparum","volume":"30","author":"Deloron","year":"1982","journal-title":"Pathol. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12936-019-2919-3","article-title":"Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs","volume":"18","author":"Foguim","year":"2019","journal-title":"Malar. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/AAC.01607-06","article-title":"Assessment and continued validation of the malaria sybr green i-based fluorescence assay for use in malaria drug screening","volume":"51","author":"Johnson","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/AAC.16.6.710","article-title":"Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique","volume":"16","author":"Desjardins","year":"1979","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/1475-2875-12-431","article-title":"In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene","volume":"12","author":"Pascual","year":"2013","journal-title":"Malar. J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1475-2875-10-268","article-title":"Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia","volume":"10","author":"Pradines","year":"2011","journal-title":"Malar. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12936-015-0586-6","article-title":"Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine","volume":"14","author":"Pascual","year":"2015","journal-title":"Malar. J."},{"key":"ref_129","unstructured":"(2024, November 09). European Medicines Agency., Available online: https:\/\/www.ema.europa.eu\/en."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1128\/AAC.05067-11","article-title":"Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum Malaria\u25bf","volume":"55","author":"Rijken","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1128\/AAC.00326-15","article-title":"Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women","volume":"59","author":"Benjamin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Saito, M., Carrara, V.I., Gilder, M.E., Min, A.M., Tun, N.W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M.K., Haohankhunnatham, W., and Konghahong, K. (2021). A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Med., 19.","DOI":"10.1186\/s12916-021-02002-8"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12936-015-0664-9","article-title":"Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim\u00ae (dihydroartemisinin\/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania","volume":"14","author":"Baiden","year":"2015","journal-title":"Malar. J."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kabanywanyi, A.M., Baiden, R., Ali, A.M., Mahende, M.K., Ogutu, B.R., Oduro, A., Tinto, H., Gyapong, M., Sie, A., and Sevene, E. (2016). Multi-Country evaluation of safety of dihydroartemisinin\/piperaquine post-licensure in african public hospitals with electrocardiograms. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164851"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12936-021-03750-x","article-title":"Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries","volume":"20","author":"Vignier","year":"2021","journal-title":"Malar. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1473-3099(18)30297-4","article-title":"Risk of sudden unexplained death after use of dihydroartemisinin\u2013piperaquine for malaria: A systematic review and Bayesian meta-analysis","volume":"18","author":"Chan","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1475-2875-12-211","article-title":"MMV in partnership: The Eurartesim\u00ae experience","volume":"12","author":"Ubben","year":"2013","journal-title":"Malar. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12936-014-0521-2","article-title":"Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children","volume":"14","author":"Nji","year":"2015","journal-title":"Malar. J."},{"key":"ref_139","unstructured":"MSF (2024, November 09). MSF Medical Guidelines for Dihydroartemisinin Piperaquine Combination. Available online: https:\/\/medicalguidelines.msf.org\/en\/viewport\/EssDr\/english\/dihydroartemisinin-piperaquine-dha-ppq-oral-16683494.html."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1475-2875-11-110","article-title":"Relationship between treatment-seeking behaviour and artemisinin drug quality in Ghana","volume":"11","author":"Klein","year":"2012","journal-title":"Malar. J."},{"key":"ref_141","unstructured":"World Health Organization (2009). Methods for Surveillance of Antimalarial Drug Efficacy, World Health Organization."},{"key":"ref_142","unstructured":"World Health Organization (2024, November 09). Monitoring Antimalarial Drug Efficacy. Available online: https:\/\/www.who.int\/teams\/global-malaria-programme\/case-management\/drug-efficacy-and-resistance\/monitoring-antimalarial-drug-efficacy."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Grande, T., Bernasconi, A., Erhart, A., Gamboa, D., Casapia, M., Delgado, C., Torres, K., Fanello, C., Llanos-Cuentas, A., and D\u2019Alessandro, U. (2007). A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001101"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e0020722","DOI":"10.1128\/aac.00207-22","article-title":"Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017","volume":"66","author":"Westercamp","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12936-018-2200-1","article-title":"Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger","volume":"17","author":"Grandesso","year":"2018","journal-title":"Malar. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12936-019-2740-z","article-title":"High cure rates and tolerability of artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania","volume":"18","author":"Mandara","year":"2019","journal-title":"Malar. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12936-017-1983-9","article-title":"Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009\u20132013)","volume":"16","author":"Nyunt","year":"2017","journal-title":"Malar. J."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"PREGACT Study Group, Pekyi, D., Ampromfi, A.A., Tinto, H., Traor\u00e9-Coulibaly, M., Tahita, M.C., Val\u00e9a, I., Mwapasa, V., Kalilani-Phiri, L., and Kalanda, G. (2016). Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. N. Engl. J. Med., 374, 913\u2013927.","DOI":"10.1056\/NEJMoa1508606"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Marwa, K., Kapesa, A., Baraka, V., Konje, E., Kidenya, B., Mukonzo, J., Kamugisha, E., and Swedberg, G. (2022). Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264339"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12936-021-03873-1","article-title":"Efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria among children in Africa: A systematic review and meta-analysis of randomized control trials","volume":"20","author":"Assefa","year":"2021","journal-title":"Malar. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1128\/AAC.02746-14","article-title":"Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam","volume":"58","author":"Thriemer","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: A multicentre, open-label, randomised clinical trial","volume":"395","author":"Tripura","year":"2020","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/infdis\/jit077","article-title":"Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: A randomized trial","volume":"207","author":"Sawa","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/cis959","article-title":"The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: An open-label, randomized, controlled trial","volume":"56","author":"Sutanto","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ebiom.2016.10.032","article-title":"The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial","volume":"13","author":"Okebe","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Bastiaens, G.J.H., Tiono, A.B., Okebe, J., Pett, H.E., Coulibaly, S.A., Gon\u00e7alves, B.P., Affara, M., Ou\u00e9draogo, A., Bougouma, E.C., and Sanou, G.S. (2018). Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190272"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","article-title":"Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: A phase 2, single-blind, randomised controlled trial","volume":"18","author":"Dicko","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_158","unstructured":"Gogtay, N., Kannan, S., Thatte, U.M., Olliaro, P.L., and Sinclair, D. (2024, November 09). Artemisinin-Based Combination Therapy for Treating Uncomplicated Plasmodium vivax Malaria. Available online: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008492.pub3\/full."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jiab351","article-title":"The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria","volume":"225","author":"Andronescu","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(18)32224-4","article-title":"Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomised, controlled, superiority trial","volume":"393","author":"Kajubi","year":"2019","journal-title":"Lancet"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kakuru, A., Jagannathan, P., Kajubi, R., Ochieng, T., Ochokoru, H., Nakalembe, M., Clark, T.D., Ruel, T., Staedke, S.G., and Chandramohan, D. (2020). Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: A randomized controlled trial. BMC Med., 18.","DOI":"10.1186\/s12916-020-01675-x"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(15)00310-4","article-title":"Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: An open-label, three-group, randomised controlled superiority trial","volume":"386","author":"Desai","year":"2015","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1016\/S2214-109X(20)30325-9","article-title":"Preventive malaria treatment among school-aged children in sub-Saharan Africa: A systematic review and meta-analyses","volume":"8","author":"Cohee","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Bojang, K., Akor, F., Bittaye, O., Conway, D., Bottomley, C., Milligan, P., and Greenwood, B. (2010). A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011225"},{"key":"ref_165","unstructured":"Cohee, L. (2024, November 09). Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens. 2023. Report No.: NCT05980156, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05980156."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/cid\/ciy218","article-title":"Intermittent preventive treatment for malaria in pregnancy: Optimization of target concentrations of dihydroartemis-inin-piperaquine","volume":"67","author":"Savic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/AAC.02667-14","article-title":"Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval","volume":"58","author":"Manning","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13063-018-2931-x","article-title":"Cluster-randomized trial of monthly malaria prophylaxis versus focused screening and treatment: A study protocol to define malaria elimination strategies in Cambodia","volume":"19","author":"Manning","year":"2018","journal-title":"Trials"},{"key":"ref_169","unstructured":"(2024, November 09). WHO Guidelines for Malaria, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588130\/."},{"key":"ref_170","unstructured":"(2022). WorldWide Antimalarial Resistance Network Methodology Study Group Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: An individual participant data meta-analysis. Malar. J., 21, 106."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/s12936-016-1535-8","article-title":"Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient","volume":"15","author":"Roseau","year":"2016","journal-title":"Malar. J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e01847","DOI":"10.1016\/j.idcr.2023.e01847","article-title":"Late dihydroartemisinin-piperaquine treatment failure of P. falciparum malaria attack related to insufficient dosing in an obese patient","volume":"33","author":"Parisey","year":"2023","journal-title":"IDCases"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1128\/AAC.00486-07","article-title":"Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria","volume":"51","author":"Price","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Zongo, I., Som\u00e9, F.A., Somda, S.A.M., Parikh, S., Rouamba, N., Rosenthal, P.J., Tarning, J., Lindegardh, N., Nosten, F., and Ou\u00e9draogo, J.B. (2014). Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103200"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Mlugu, E.M., Minzi, O.M.S., Johansson, M., Kamuhabwa, A.A.R., and Aklillu, E. (2024). Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy. BMC Pharmacol. Toxicol., 25.","DOI":"10.1186\/s40360-024-00762-6"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2011.254","article-title":"Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria","volume":"91","author":"Tarning","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Byakika-Kibwika, P., Ssenyonga, R., Lamorde, M., Blessborn, D., and Tarning, J. (2019). Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4647-2"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1128\/AAC.05756-11","article-title":"Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria","volume":"56","author":"Tarning","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jit078","article-title":"Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants","volume":"207","author":"Creek","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"taad159","DOI":"10.1093\/jtm\/taad159","article-title":"Out of Africa: Increasing reports of artemether-lumefantrine treatment failures of uncomplicated Plasmodium falciparum infection","volume":"30","author":"Halsey","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_181","unstructured":"(2024, November 09). Artemisinin Resistance and Artemisinin-Based Combination Therapy Efficacy (December 2018). Available online: https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/who-cds-gmp-2018-26-eng.pdf."},{"key":"ref_182","first-page":"281","article-title":"Field observations on the antimalarial piperaquine","volume":"95","author":"Chen","year":"1982","journal-title":"Chin. Med. J."},{"key":"ref_183","first-page":"602","article-title":"Randomised comparison on the treatment of falciparum malaria with dihydroartemisinin and piperaquine","volume":"73","author":"Guo","year":"1993","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_184","first-page":"163","article-title":"In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan Province","volume":"7","author":"Lan","year":"1989","journal-title":"Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12936-023-04658-4","article-title":"Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin\u2013piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia","volume":"22","author":"Rahmasari","year":"2023","journal-title":"Malar. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgar.2023.10.001","article-title":"Dihydroartemisinin-piperaquine efficacy in Plasmodium falciparum treatment and prevalence of drug-resistant molecular markers along China-Myanmar border in 2014\u20132023","volume":"35","author":"Liu","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","article-title":"Triple Artemisinin-Based Combination Therapies for Malaria\u2014A New Paradigm?","volume":"37","author":"Amaratunga","year":"2021","journal-title":"Trends Parasitol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"taad012","DOI":"10.1093\/jtm\/taad012","article-title":"Unusual blood smear with multiple stages of Plasmodium falciparum infection and intraleukocytic malaria pigments in an expatriate with severe malaria and delayed clearance of parasites","volume":"30","author":"Javelle","year":"2023","journal-title":"J. Travel Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s12936-016-1572-3","article-title":"Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia","volume":"15","author":"Gobbi","year":"2016","journal-title":"Malar. J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e01892-17","DOI":"10.1128\/AAC.01892-17","article-title":"Plasmodium falciparum recrudescence two years after treatment of an uncomplicated infection without return to an area where malaria is endemic","volume":"62","author":"Malvy","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s15010-018-1174-9","article-title":"Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia","volume":"46","author":"Russo","year":"2018","journal-title":"Infection"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijid.2022.06.009","article-title":"Artesunate and dihydroartemisinin-piperaquine treatment failure in a severe Plasmodium falciparum malaria case imported from Republic of C\u00f4te d\u2019Ivoire","volume":"122","author":"Motta","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"taae043","DOI":"10.1093\/jtm\/taae043","article-title":"Dihydroartemisinin-piperaquine treatment failure of uncomplicated Plasmodium falciparum malaria infection in a traveller","volume":"31","author":"Delandre","year":"2024","journal-title":"J. Travel Med."},{"key":"ref_194","first-page":"001009","article-title":"Genomic variation during culture adaptation of genetically complex Plasmodium falciparum clinical isolates","volume":"9","author":"Claessens","year":"2023","journal-title":"Microb. Genom."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cyto.990040307","article-title":"Analysis of malaria parasite-infected blood by flow cytometry","volume":"4","author":"Jacobberger","year":"1983","journal-title":"Cytometry"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/AAC.00835-15","article-title":"Evidence of Plasmodium falciparum Malaria Multidrug resistance to artemisinin and piperaquine in Western Cambodia: Dihydroartemisinin-piperaquine open-label multicenter clinical assessment","volume":"59","author":"Leang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12936-020-03339-w","article-title":"Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: In vitro genotypic and phenotypic characterization","volume":"19","author":"Boonyalai","year":"2020","journal-title":"Malar. J."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12936-019-2916-6","article-title":"Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?","volume":"18","author":"Gendrot","year":"2019","journal-title":"Malar. J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","article-title":"A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa","volume":"16","author":"Ndwiga","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S1473-3099(20)30493-X","article-title":"Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: A systematic review","volume":"21","author":"Kayiba","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ng.2624","article-title":"Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia","volume":"45","author":"Miotto","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.12688\/wellcomeopenres.18681.1","article-title":"Pf7: An open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples","volume":"8","author":"Abdelraheem","year":"2023","journal-title":"Wellcome Open Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6828\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:35Z","timestamp":1760113895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/22\/6828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":202,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13226828"],"URL":"https:\/\/doi.org\/10.3390\/jcm13226828","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}